Leerink Partners assumed coverage on shares of Harrow (NASDAQ:HROW – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $45.00 price target on the stock.
A number of other research firms have also weighed in on HROW. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Cantor Fitzgerald dropped their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $63.00 target price on shares of Harrow in a report on Tuesday, August 11th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $66.38.
View Our Latest Stock Analysis on HROW
Harrow Trading Down 0.8%
Harrow (NASDAQ:HROW – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The company had revenue of $70.66 million for the quarter, compared to the consensus estimate of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%.
Insider Buying and Selling at Harrow
In related news, insider Amir Shojaei sold 11,250 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 11,250 shares of the company’s stock, valued at approximately $450,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.80% of the company’s stock.
Institutional Trading of Harrow
A number of large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in Harrow by 102.5% in the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after acquiring an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares during the period. Strs Ohio bought a new stake in shares of Harrow in the 1st quarter worth approximately $149,000. Legal & General Group Plc grew its holdings in Harrow by 12.4% during the second quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock valued at $939,000 after purchasing an additional 3,384 shares during the period. Finally, Rhumbline Advisers grew its holdings in Harrow by 9.3% during the second quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock valued at $1,434,000 after purchasing an additional 3,994 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.
About Harrow
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
Featured Articles
- Five stocks we like better than Harrow
- Life Time Keeps Beating Expectations, But Insiders Are Selling Into Strength
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
